WORCESTER, Mass. and TORONTO, Dec. 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today that a group of physicians led by Professor Paolo Pozzilli at the University Campus Bio-Medico in Rome, Italy, will provide an update on results of using Generex Oral-lyn™ as it pertains to prediabetes at the forthcoming International Diabetes Federation (IDF) Congress, to be held in Dubai, December 3rd-8th, 2011.
The paper is entitled "Buccal Spray Insulin for The Treatment of Impaired Glucose Tolerance" and is presented by Dr. Y.M. Khazrai of Dr. Pozzilli's research team.
The study results confirm and significantly extend previous beneficial results showing that subjects with impaired glucose tolerance (IGT) treated with the Generex Oral-lyn™ buccal insulin spray achieved a significant reduction of 0.3% in HbA1c compared to the control group (∆ HbA1c 0'- 6 month -0.3% vs +0.09%, p= 0.002). Although the decrease in body weight in Generex Oral-lyn™ treated subjects did not reach significance in this short term study, there were no reports of hypoglycemia or other adverse events observed during the study period compared to control subjects. These preliminary results suggest that the addition of Generex Oral-lyn™ can be an effective treatment compared to diet and physical exercise alone in subjects with IGT in reducing HbA1c and doing so without adverse effects.
"These results suggest Generex Oral-lyn™ will be an important therapy tool for adults with prediabetes conditions of IGT and elevated blood-sugar levels," said Dr. James H. Anderson, Jr., MD, FFPM, FACE, Generex's Senior Scientific A
|SOURCE Generex Biotechnology Corporation|
Copyright©2010 PR Newswire.
All rights reserved